Clinical Trial Update: Study Evaluating Safety and Tolerability of Inotuzumab Ozogamicin (CMC-544) in Japanese Patients With B-cell Non-Hodgkin's Lymphoma (NHL) [Phase 1]

View source ↗

Summary

This trial evaluated safety and tolerability of inotuzumab ozogamicin in Japanese patients with B-cell non-Hodgkin lymphoma; the Phase 1 study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Besponsa (inotuzumab ozogamicin)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Lymphoma, B-Cell | Phase 1 | Status: COMPLETED